Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - BIOMIMETIC THERAPEUTICS, INC. | v316633_ex99-1.htm |
| EX-99.2 - EXHIBIT 99.2 - BIOMIMETIC THERAPEUTICS, INC. | v316633_ex99-2.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 21, 2012 (June 21, 2012)
BIOMIMETIC THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-51934 | 62-1786244 |
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
389 Nichol Mill Lane, Franklin, Tennessee 37067
(Address of principal executive offices)
(615) 844-1280
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On June 21, 2012, BioMimetic Therapeutics, Inc. (the “Company”) issued a press release announcing that Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of Toronto and St. Michaels Hospital and lead investigator, presented the results of a Canadian registration study comparing Augment® Injectable Bone Graft (AIBG) to autograft in foot and ankle fusion surgery. The presentation took place on Thursday, June 21, 2012, at the American Orthopaedic Foot and Ankle Society (AOFAS) annual meeting. As presented by Dr. Daniels, the trial met its primary endpoint of non-inferiority of AIBG to autograft as assessed by CT scan at six months.
A copy of the press release and the slides presented at the meeting are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release dated June 21, 2012
99.2 Slide Presentation
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BIOMIMETIC THERAPEUTICS, INC. | |||
| By: | /s/ Larry Bullock | ||
| Name: Larry Bullock | |||
| Title: Chief Financial Officer | |||
Date: June 21, 2012